HK1058032A1 - Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors - Google Patents

Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors

Info

Publication number
HK1058032A1
HK1058032A1 HK0100042A HK0100042A HK1058032A1 HK 1058032 A1 HK1058032 A1 HK 1058032A1 HK 0100042 A HK0100042 A HK 0100042A HK 0100042 A HK0100042 A HK 0100042A HK 1058032 A1 HK1058032 A1 HK 1058032A1
Authority
HK
Hong Kong
Prior art keywords
blood
sup
compounds
inhibiting
formation
Prior art date
Application number
HK0100042A
Other languages
English (en)
Inventor
Wenxi Pan
Tianbao Lu
Thomas P Markotan
Bruce E Tomczuk
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of HK1058032A1 publication Critical patent/HK1058032A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
HK0100042A 2000-10-06 2004-01-02 Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors HK1058032A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23813200P 2000-10-06 2000-10-06
PCT/US2001/031249 WO2002028825A2 (en) 2000-10-06 2001-10-05 Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl- substituted phenyl acetamides as protease inhibitors

Publications (1)

Publication Number Publication Date
HK1058032A1 true HK1058032A1 (en) 2004-04-30

Family

ID=22896640

Family Applications (1)

Application Number Title Priority Date Filing Date
HK0100042A HK1058032A1 (en) 2000-10-06 2004-01-02 Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors

Country Status (26)

Country Link
US (3) US6521663B2 (no)
EP (1) EP1324981B1 (no)
JP (1) JP4256160B2 (no)
KR (1) KR20030045103A (no)
CN (1) CN1315803C (no)
AT (1) ATE337299T1 (no)
AU (2) AU2002211464B2 (no)
BR (1) BR0114263A (no)
CA (1) CA2423883A1 (no)
CY (1) CY1106243T1 (no)
DE (1) DE60122546T2 (no)
DK (1) DK1324981T3 (no)
ES (1) ES2269474T3 (no)
HK (1) HK1058032A1 (no)
HR (1) HRP20030252A2 (no)
HU (1) HUP0303149A3 (no)
IL (1) IL155160A0 (no)
MX (1) MXPA03002998A (no)
NO (1) NO20031390L (no)
NZ (1) NZ525438A (no)
PL (1) PL361185A1 (no)
PT (1) PT1324981E (no)
RU (1) RU2003113205A (no)
UA (1) UA75093C2 (no)
WO (1) WO2002028825A2 (no)
ZA (1) ZA200303091B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75093C2 (en) * 2000-10-06 2006-03-15 Dimensional Pharm Inc Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors
US6610701B2 (en) * 2001-02-09 2003-08-26 Merck & Co., Inc. Thrombin inhibitors
WO2003043624A1 (en) * 2001-11-16 2003-05-30 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US7759513B2 (en) * 2003-02-21 2010-07-20 Nigu Chemie Gmbh Photolabile protective groups for improved processes to prepare oligonucleotide arrays
US7550474B2 (en) * 2003-04-10 2009-06-23 Johnson & Johnson Pharmaceuticals Research & Development, L.L.C. Substituted phenyl acetamides and their use as protease inhibitors
JP2007525460A (ja) 2003-04-25 2007-09-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ｃ−ｆｍｓキナーゼ阻害剤
US7427683B2 (en) * 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
US7790724B2 (en) 2003-04-25 2010-09-07 Janssen Pharmaceutica N.V. c-fms kinase inhibitors
US7914705B2 (en) * 2005-01-10 2011-03-29 Robert Eliot Sisson Flowable electrical conductive liquid
HU0500126D0 (en) * 2005-01-26 2005-04-28 Sanofi Aventis New compounds and process for their preparation
EP1893601A1 (en) * 2005-06-17 2008-03-05 AstraZeneca AB Thrombin inhibiting 2-oxo-1, 2, 5, 6-tetrahydropyridine derivatives
WO2007120729A2 (en) * 2006-04-12 2007-10-25 Merck & Co., Inc. Pyridyl amide t-type calcium channel antagonists
RU2353619C2 (ru) * 2007-06-28 2009-04-27 Общество С Ограниченной Ответственностью "Бионика" Новые соединения, обладающие функцией антикоагулянтов, фармацевтические композиции на их основе для лечения тромботических состояний и плазмозамещающий раствор для коррекции гиперкоагуляционных нарушений при гемодилюции
RU2354647C2 (ru) * 2007-06-28 2009-05-10 Общество С Ограниченной Ответственностью "Бионика" Новые соединения, обладающие функцией ингибиторов тромбина, и фармацевтические композиции на их основе
CN101665465B (zh) * 2007-09-19 2011-09-07 复旦大学 一种含胍基杂环化合物凝血酶抑制剂及其制备方法
AU2008317353B2 (en) * 2007-10-24 2014-08-07 Merck Sharp & Dohme Llc Heterocycle phenyl amide T-type calcium channel antagonists
CA2818522C (en) * 2010-12-02 2016-05-17 Becton, Dickinson And Company Blood collection devices containing blood stabilization agent
RU2019121905A (ru) 2010-12-31 2019-09-03 Астразенека Юкей Лимитед Ингибиторы аргиназы и способы их применения
AU2012255137A1 (en) 2011-05-17 2013-12-12 The Brigham And Women's Hospital, Inc. Improved platelet storage using a sialidase inhibitor
US9788539B2 (en) 2011-05-17 2017-10-17 Velico Medical, Inc. Platelet protection solution having beta-galactosidase and sialidase inhibitors
EP2903430A1 (en) 2012-10-05 2015-08-12 Velico Medical, Inc. Platelet additive solution having a beta-galactosidase inhibitor
RU2524647C1 (ru) * 2012-12-25 2014-07-27 Государственное Бюджетное Учреждение Санкт-Петербургский Научно-Исследовательский Институт Скорой Помощи Им. И.И. Джанелидзе" Способ лечения синдрома эндогенной интоксикации, обусловленного гиперпротеолизом
WO2014120886A1 (en) 2013-01-30 2014-08-07 Velico Medical, Inc. Platelet additive solution having a self-assembling hydrogel-forming peptide
WO2015143376A1 (en) * 2014-03-21 2015-09-24 Nivalis Therapeutics, Inc. Novel compounds for the treatment of cystic fibrosis
PL3325482T3 (pl) 2015-07-21 2021-01-11 Immunogen, Inc. Sposoby otrzymywania cytotoksycznych pochodnych benzodiazepiny
WO2018216012A1 (en) * 2017-05-24 2018-11-29 Ramot At Tel-Aviv University Ltd. Chemiluminescent probes for imaging/detection of proteases

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084466A (en) 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2075154A1 (en) * 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
DE4208051A1 (de) 1992-03-13 1993-09-16 Bayer Ag Substituierte phenylessigsaeureamide
DE4319887A1 (de) 1993-06-16 1994-12-22 Hoechst Schering Agrevo Gmbh Arylacetamide, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Fungizide
CZ29996A3 (en) 1993-08-12 1996-09-11 Astra Ab Amidine derivatives with activities of nitrogen oxide sythetase
US5885967A (en) 1994-03-04 1999-03-23 Eli Lilly And Company Antithrombotic agents
JPH0892224A (ja) 1994-09-16 1996-04-09 Kumiai Chem Ind Co Ltd ３，５−置換フェニルトリアゾール誘導体および殺虫、殺ダニ剤
JP3570752B2 (ja) 1994-09-22 2004-09-29 三井化学株式会社 ４−置換カルボニルクマリン誘導体、およびこれを用いた可視光感光性組成物
DE19507822B4 (de) 1995-02-21 2006-07-20 Schering Ag Substituierte DTPA-Monoamide der zentralen Carbonsäure und deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik und Therapie sowie Verfahren zur Herstellung der Komplexe und Mittel
US5741819A (en) * 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
US5721214A (en) 1995-06-07 1998-02-24 Cor Therapeutics, Inc. Inhibitors of factor Xa
WO1997001338A1 (en) * 1995-06-27 1997-01-16 Merck & Co., Inc. Pyridinone-thrombin inhibitors
CZ92298A3 (cs) 1995-09-29 1998-07-15 3-Dimensional Pharmaceuticals, Inc. Inhibitory guanidin proteasy
EP0892780B1 (en) 1996-02-22 2002-11-20 Bristol-Myers Squibb Pharma Company M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS
DE19615262A1 (de) 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide
WO1997049404A1 (en) 1996-06-25 1997-12-31 Eli Lilly And Company Anticoagulant agents
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
DE19642863A1 (de) 1996-10-17 1998-04-23 Bayer Ag Amide
TW499412B (en) 1996-11-26 2002-08-21 Dimensional Pharm Inc Aminoguanidines and alkoxyguanidines as protease inhibitors
GB9703201D0 (en) 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
SI0966436T1 (en) 1997-02-21 2003-04-30 Bayer Aktiengesellschaft Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
WO1998057926A1 (en) 1997-06-16 1998-12-23 American Home Products Corporation Elevation of hdl cholesterol by n-[2-[ (aminothioxomethyl)hydrazono] -2-arylethyl]amides
US6049006A (en) 1997-06-16 2000-04-11 American Home Products Corp. Elevation of HDL cholesterol by N-[2-[(aminothioxomethyl) hydrazono]-2-arylethyl]amides
AU7691298A (en) 1997-06-16 1999-01-04 American Home Products Corporation Elevation of hdl cholesterol by n-{4-{ (aminothioxomethyl) hydrazono} -4-arylbutyl}amides
US6034272A (en) 1997-06-16 2000-03-07 American Home Products Corporation Elevation of HDL cholesterol by N-[4-[(aminothioxomethyl) hydrazono]-4-arylbutyl]amides
AU751412B2 (en) * 1997-11-26 2002-08-15 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
CA2260499A1 (en) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
US6344486B1 (en) * 1998-04-03 2002-02-05 3-Dimensional Pharmaceuticals, Inc. Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors
WO1999055688A1 (en) 1998-04-27 1999-11-04 Warner-Lambert Company Substituted diarylalkyl amides as calcium channel antagonists
DE19824470A1 (de) 1998-05-30 1999-12-02 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE19937494A1 (de) * 1999-08-07 2001-02-08 Boehringer Ingelheim Pharma Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
AU2001243598A1 (en) 2000-03-13 2001-09-24 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
UA75093C2 (en) * 2000-10-06 2006-03-15 Dimensional Pharm Inc Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors

Also Published As

Publication number Publication date
CY1106243T1 (el) 2011-06-08
WO2002028825A3 (en) 2002-06-13
AU2002211464B2 (en) 2006-06-22
DE60122546T2 (de) 2007-09-13
RU2003113205A (ru) 2004-11-10
JP2004510759A (ja) 2004-04-08
NO20031390L (no) 2003-06-03
KR20030045103A (ko) 2003-06-09
ZA200303091B (en) 2004-07-22
US20020061872A1 (en) 2002-05-23
BR0114263A (pt) 2004-03-02
ATE337299T1 (de) 2006-09-15
HRP20030252A2 (en) 2005-10-31
HUP0303149A3 (en) 2009-05-28
US6521663B2 (en) 2003-02-18
PT1324981E (pt) 2006-12-29
US6900231B2 (en) 2005-05-31
DE60122546D1 (en) 2006-10-05
CA2423883A1 (en) 2002-04-11
AU1146402A (en) 2002-04-15
NZ525438A (en) 2004-09-24
CN1568307A (zh) 2005-01-19
MXPA03002998A (es) 2004-02-12
CN1315803C (zh) 2007-05-16
IL155160A0 (en) 2003-10-31
ES2269474T3 (es) 2007-04-01
JP4256160B2 (ja) 2009-04-22
EP1324981B1 (en) 2006-08-23
NO20031390D0 (no) 2003-03-26
UA75093C2 (en) 2006-03-15
US20050159457A1 (en) 2005-07-21
HUP0303149A2 (hu) 2004-01-28
EP1324981A2 (en) 2003-07-09
DK1324981T3 (da) 2006-12-04
PL361185A1 (en) 2004-09-20
WO2002028825A2 (en) 2002-04-11
US20030073833A1 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
AU1146402A (en) Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl- substituted phenyl acetamides as protease inhibitors
EP1589029A3 (en) Pyrazinone protease inhibitors
WO1998023565A3 (en) Aminoguanidines and alkoxyguanidines as protease inhibitors
BR9815325A (pt) Heteroaril, aminoguanidinas e alcóxiguanidinas eseu uso como inibidores da protease
ATE270269T1 (de) Boenzoesäureamid und -sulfonamid substituierte aminoguanidine und alkoxyguanidine als proteaseinhibitoren
ATE338030T1 (de) Amidine-inhibitoren der serine-proteasen
DE60040345D1 (de) VERFAHREN ZUR HERSTELLUNG EINER REVERSIBEL INAKTIVEN, ANGESäUERTEN PLASMINZUSAMMENSETZUNG
WO2004091613A3 (en) Substituted phenyl acetamides and their use as protease inhibitors
WO2002006248A3 (en) Cyclic oxyguanidine pyrazinones as protease inhibitors
DE60005351D1 (de) Heteroaryl protease inhibitoren und diagnostische bilderzeugungsmittel
MXPA03000963A (es) Inhibidores de oxiguanidina ciclica proteasa.

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF PROPRIETOR FROM ORTHO-MCNEIL PHARMACEUTICALS, INC. TO ORTHO-MCNEIL PHARMACEUTICAL, INC

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20101005